TY - JOUR T1 - Short-term improvement of mental health after a COVID-19 vaccination JF - medRxiv DO - 10.1101/2022.02.22.22271327 SP - 2022.02.22.22271327 AU - Charilaos Chourpiliadis AU - Anikó Lovik AU - Anna K. Kähler AU - Unnur A. Valdimarsdóttir AU - Emma M. Frans AU - Fredrik Nyberg AU - Patrick F. Sullivan AU - Fang Fang Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/27/2022.02.22.22271327.abstract N2 - Importance The role of COVID-19 vaccination on the mental health of the general population remains poorly understood.Objective To assess the short-term change of depressive and anxiety symptoms in relation to COVID-19 vaccination among Swedish adults.Design A prospective cohort study with monthly data collections on self-reported depressive and anxiety symptoms from December 2020 to October 2021 and COVID-19 vaccination from July to October 2021.Setting The Omtanke2020 Study, Sweden.Participants 7,925 participants of the Omtanke2020 study with complete data on depressive and anxiety symptoms and vaccination status.Intervention(s) or Exposure(s) Receiving the first or second dose of a COVID-19 vaccine.Main outcomes(s) and Measure(s) Binary measures of depression (PHQ-9, cut-off ≥10) and anxiety (GAD-7, cut-off ≥10) one month before the first dose, one month after the first dose, and, if applicable, one month after the second dose. For individuals not vaccinated or chose to not report vaccination status (unvaccinated individuals), we selected three monthly measures of PHQ-9 and GAD-7 with 2-month intervals in-between based on data availability.Results 5,079 (64.1%) individuals received two doses of COVID-19 vaccine, 1,977 (24.9%) received one dose, 305 (3.9%) were not vaccinated, and 564 (7.1%) chose not to report vaccination status. There was a lower prevalence of depression and anxiety among vaccinated, compared with unvaccinated, individuals, especially after the second dose. Among individuals receiving two doses of vaccine, the prevalence of depression and anxiety was lower after both first (aRR=0.82, 95%CI 0.76-0.88 for depression; aRR=0.81, 95%CI 0.73-0.89 for anxiety) and second (aRR=0.79, 95%CI 0.73-0.85 for depression; aRR=0.73, 95%CI 0.66-0.81 for anxiety) dose, compared with before vaccination. Similar results were observed among individuals receiving only one dose (aRR=0.76, 95%CI 0.68-0.84 for depression; aRR=0.82, 95%CI 0.72-0.94 for anxiety, comparing after first dose to before vaccination). These results were independent of age, sex, recruitment type, body mass index, smoking, relationship status, history of psychiatric disorder, number of comorbidities, COVID-19 infection status, and seasonality.Conclusions and Relevance We observed a positive short-term change in depressive and anxiety symptoms among adults receiving a COVID-19 vaccine in the current pandemic.Question Is COVID-19 vaccination associated with a short-term change in mental health?Findings This longitudinal study included 7,925 Swedish adults with self-reported COVID-19 vaccination and symptoms of mental health responding from December 2020 to October 2021. The prevalence of depressive or anxiety symptoms was lower one month after vaccination compared to one month before vaccination. The effect size was greater among individuals receiving two doses of vaccine, compared with those receiving only one dose.Meaning Receiving vaccination against COVID-19 is associated with short-term improvement in mental health.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by NordForsk (project No. 105668) and Horizon2020 (CoMorMent, 847776).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved (DNR 2020-01785) by the Swedish Ethical Review Authority on 3 June 2020.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available for a specified purpose after approval by the institution and the principal investigator of the Omtanke2020 study and with a signed data access agreement. ER -